Elicitation of expert prior opinion: Application to the MYPAN trial in childhood polyarteritis nodosa

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Hampson, Lisa V ^a   Whitehead, John ^a   Eleftheriou, Despina ^b   Tudur Smith, Catrin ^c   Jones, Rachel ^d   Jayne, David ^e   Hickey, Helen ^c   Beresford, Michael W ^c   Bracaglia, Claudia ^f   Caldas, Afonso ^g   Cimaz, Rolando ^h   Dehoorne, Joke ⁱ   Dolezalova, Pavla ^j   Friswell, Mark ^k   Jelusic, Marija ^l   Marks, Stephen D ^m   Martin, Neil ⁿ   McMahon, Anne Marie ^o   Peitz, Joachim ^p   Van Royen Kerkhof, Annet ^q   Soylemezoglu, Oguz ^r   Brogan, Paul A ^b   more..

^a LANCASTER UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g University of Porto   (Portugal)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j CHARLES UNIVERSITY   (Czech Republic)

^k Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

^l UNIVERSITY OF ZAGREB   (Croatia)

^m GREAT ORMOND STREET HOSPITAL   (United Kingdom)

ⁿ ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^o SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^p UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^q UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^r GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADOLESCENT; ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; BAYES THEOREM; CHILD; CLINICAL ARTICLE; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MATHEMATICAL MODEL; MEDICAL EXPERT; OUTCOME ASSESSMENT; POLYARTERITIS NODOSA; RANDOMIZED CONTROLLED TRIAL; RARE DISEASE; REMISSION; STRUCTURED QUESTIONNAIRE; STUDY DESIGN; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASES; TREATMENT OUTCOME;

BAYES THEOREM; CHILD; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; POLYARTERITIS NODOSA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; TREATMENT OUTCOME;

EID: 84926673274     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120981     Document Type: Article

References (22)

1. Department of Health. Consultation on the United Kingdom Plan for Rare Diseases. 2013. Available: www.gov.uk/government/uploads/system/uploads/attachment-data/file/215141/dh-132883.pdf. Accessed 2014 Mar 30.
2. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ 1995; 311:1621-1625. PMID: 8555809
3. Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. J Clin Epidemiol 2011; 64:1085-1094. doi: 10.1016/j.jclinepi.2010.12.019 PMID: 21530171
4. Tan S-B, Chung Y-F A, Tai B-C, Cheung Y-B, Machin D. Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma. Control Clin Trials 2003; 24: 110-121. PMID: 12689733
5. Hiance A, Chevret S, Levy V. A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial. J Clin Epidemiol 2009; 62: 431-437. doi: 10.1016/j.jclinepi.2008.04.009 PMID: 19010642
6. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Hawker GA, Feldman BM. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. J Rheumatol 2011; 38:462-469. doi: 10.3899/jrheum.100632 PMID: 21159827
7. Hampson LV, Whitehead J, Eleftheriou D, Brogan P. Bayesian methods for the design and interpretation of clinical trials in very rare diseases. Stat Med 2014; 33:4186-4201. doi: 10.1002/sim.6225 PMID: 24957522
8. Dillon MJ, Eleftheriou D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol 2010; 25:1641-1652. doi: 10.1007/s00467-009-1336-1 PMID: 19946711
9. Eleftheriou D, Dillon MJ, Tullus K, Marks SD, Pilkington CA, Roebuck DJ et al. Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years. Arthritis Rheum 2013; 65:2476-2485. doi: 10.1002/art.38024 PMID: 23754739
10. Bagenstoss AH, Shick RM, Polley HF. The effect of cortisone on the lesions of periarteritis nodosa. Am J Pathol 1951; 27:537-559. PMID: 14846911
11. Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36:1290-1297. PMID: 9448590
12. Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Généreau T et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38:1638-1645. PMID: 7488285
13. Guillevin L, Cohen P, Mahr A, Arène JP, Mouthon L, Puéchal X et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003; 49:93-100. PMID: 12579599
14. Ribi C, Cohen P, Pagnoux C, Mahr A, Arène JP, Puéchal X et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 2010; 62:1186-1197. doi: 10.1002/art.27340 PMID: 20131268
15. Dolezalova P, Price-Kuehne FE, Özen S, Benseler SM, Cabral DA, Anton J et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis 2013; 72:1628-1633. doi: 10.1136/annrheumdis-2012-202111 PMID: 23100606
16. Hiemstra TF, Jones RB, Jayne DR. Treatment of Primary Systemic Vasculitis with the Inosine Monophosphate Dehydrogenase Inhibitor Mycophenolic Acid. Nephron Clin Pract 2010; 116:c1-c10. doi: 10.1159/000314543 PMID: 20484933
17. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010; 69:798-806. doi: 10.1136/ard.2009.116657 PMID: 20413568
18. Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child 2011; 96:596-601. doi: 10.1136/adc.2010.188946 PMID: 21317432
19. Morita S, Thall PF, Müller P. Determining the effective sample size of a parametric prior. Biometrics 2008; 64:595-602. PMID: 17764481
20. R Core Team. R: A language and environment for statistical computing; 2013. R Foundation for Statistical Computing, Vienna, Austria.
21. RStudio and Inc. Shiny: Web Application Framework for R; 2013. R package version 0.7.099.
22. Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. Methods to elicit beliefs for Bayesian priors: a systematic review. J Clin Epidemiol 2010; 63:355-369. doi: 10.1016/j.jclinepi.2009.06.003 PMID: 19716263